

Alex J. Mayer
Cabinet Secretary

Cynthia Beane, MSW, LCSW
Commissioner

*Pharmaceutical and Therapeutics
(P&T)
Committee
April 23, 2025*

Location: Webex only
Time: Executive Session 2:00 PM - 3:00 PM
Time: Open Session 3:00 PM – 5:00 PM
(304) 558-1700

AGENDA

- I. Executive Session- 2:00PM-3:00PM
- II. Call to Order – Call in information for the 3:00 PM Open Session is
+1 952-222-7450 meeting code 259 702 812#
Join on your computer, mobile app or room device
[Join the meeting now](#)
Meeting ID: 236 023 243 424
Passcode: c8yW77mv
[Download Teams](#) | [Join on the web](#)
- III. Welcome and Introductions
- IV. Housekeeping Items/Updates
 - a. Approval of the January 22, 2025, Minutes
 - b. PDL Compliance/Generic Percent Report Updates
- V. Public Comments (*Agenda classes only*) – Public comments for this meeting will only be accepted in writing. Comments need to be sent via email to Vicki Cunningham (Vicki.M.Cunningham@wv.gov) no later than April 9, 2025. Comments will be forwarded to committee members prior to the meeting for their review and consideration.

Representatives of drug manufacturers being presented at P&T can register to be on hand to answer any questions put forth by P&T committee members. Registrants must provide a name, email address, name of drug



and company they are representing, and provide a completed [disclosure form](#) to the email address above no later than April 9, 2025.

VI. New Business

a. New Drug Reviews

- i. Androgenic Agents
 - 1. Azmiro (testosterone cypionate) injection
- ii. Antihemophilia Agents
 - 1. Alhemo (concizumab-mtci)
- iii. Antipsychotics, Atypical and Combination
 - 1. Opipza (aripiprazole) film, soluble
- iv. Cytokine and CAM Antagonists
 - 1. Steqeyma (ustekinumab-stba)
 - 2. Yesintek (ustekinumab-kfce)
 - 3. Otulfi (ustekinumab-aaaz)
 - 4. Pyzchiva (ustekinumab-ttwe)
 - 5. Selarsdi (ustekinumab-aekn)
- v. Immunomodulators, Atopic Dermatitis
 - 1. Nemludio (nemolizumab-iltio) injection, powder
- vi. Lipotropics, Other (non-statin)
 - 1. Tryngolza (olezarsen)
- vii. Obstructive Sleep Apnea
 - 1. Zepbound (tirzepatide)

VII. Old Business

VIII. Other Business

IX. Next Meeting – August 27, 2025 (*Virtual*)

X. Adjournment

